+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis



Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis



World Journal of Surgical Oncology 14(1): 237



Non-small cell lung cancer (NSCLC) is the most frequent cause of cancer deaths worldwide. The targeted therapy had made important progress in recent years, but few potential predictive biomarkers for prognosis of NSCLC patients were identified. Angiopoietin-2 (Ang-2), a cytokine upregulated in tumor endothelial cells and some tumor cells including NSCLC, is a partial agonist and antagonist of angiopoietin-1 (Ang-1). Ang-1 is another ligand for the tyrosine kinase receptor Tie2; it promotes recruitment of pericytes and smooth muscle cells, stabilizing vascular networks by binding to Tie2. Although many studies mainly considered that Ang-2 correlated with progression and prognosis of NSCLC significantly, there are much conflicting and controversial data. Therefore, we conducted a meta-analysis to assess the relationship between Ang-2 and prognosis, a clinical outcome of NSCLC. The search was based on major databases from PubMed, Cochrane Library, EMBASE, and CNKI, and 20 eligible publications (range from 2002 to 2015) are included in our meta-analysis with 2011 NSCLC patients in total. These studies illuminated the correlation between the expression of Ang-2 and NSCLC, based on either prognostic factors or clinicopathological features. Pooled calculations were carried out on the odds ratio (OR) and the corresponding 95 % confidence interval (CI) to perform this meta-analysis, and all statistical analyses were carried out by STATA 12.0 and Review Manager 5.3. According to our results, the expression of Ang-2 in NSCLC tissues was significantly higher than that in normal lung tissues, indicating that Ang-2 over-expression may be a predictive marker (pooled OR = 5.09, corresponding 95 % confidence interval (95 % CI) 3.10-8.36, p = 0.000). In addition, our pooled data showed that Ang-2 expression was positively correlated with tumor stages (pooled OR = 3.58, 95 % CI 2.40-5.35, p = 0.000), differentiation (pooled OR = 0.65, 95 % CI 0.45-0.94, p = 0.02), lymphatic invasion (pooled OR = 3.15, 95 % CI 1.97-5.03, p = 0.000), and poor survival (pooled OR = 1.93, 95 % CI 1.47-2.52, p = 0.000) of NSCLC, but seems to have no significant impact on tumor size (pooled OR = 1.09, 95 % CI 0.59-2.00, p = 0.78). These results demonstrate that Ang-2 expression significantly correlated with poor prognosis for patients with NSCLC.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637624

Download citation: RISBibTeXText

PMID: 27589869

DOI: 10.1186/s12957-016-0992-4


Related references

Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis. Oncotarget 8(16): 27137-27144, 2017

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. European Journal of Surgical Oncology 41(4): 450-456, 2015

Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: A meta-analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry 451(Pt B): 208-214, 2016

Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer. Clinical Laboratory 63(1): 59-65, 2017

Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clinical Cancer Research 6(10): 4055-4063, 2000

Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. Journal of Thoracic Disease 5(1): 40-47, 2013

Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research 5(2): 202-207, 2016

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 81(1): 1-10, 2014

Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis. International Journal of Clinical and Experimental Medicine 8(8): 12765-12773, 2015

Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis. Tumour Biology 35(8): 7383-7389, 2015

Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Bioscience Trends 7(1): 42-49, 2013

Prognostic value of Ki-67 in stage I non-small-cell lung cancer: A meta-analysis involving 1931 patients. Pathology, Research and Practice 2019, 2019

Prognostic value of wingless-type proteins in non-small cell lung cancer patients: a meta-analysis. Translational Lung Cancer Research 5(4): 436-442, 2016

Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research 6(1): 97-108, 2017

Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. Oncotargets and Therapy 8: 3361-3369, 2015